Bifikafusp alfa

Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性[1]。 Animal Model: Female NMRI nude mice with MiaPaca-A2 xenografts[1] Dosage: 1.43 and 4.29 MIU/kg Administration: Intraperitoneal injection; daily; for 10 days Result: Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.

[1]. Wagner K, et, al. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008 Aug 1;14(15):4951-60.